Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard’s small molecule product candidates are based on more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies. Longboard is also evaluating LP659, a centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, in development for the potential treatment of multiple neurological diseases, and LP143, a centrally acting, full cannabinoid type 2 receptor (CB2) agonist, in development for the potential treatment of central nervous system (CNS) diseases and disorders.
View Top Employees from Longboard PharmaceuticalsWebsite | http://www.longboardpharma.com/ |
Employees | 57 (44 on RocketReach) |
Founded | 2020 |
Address | 4275 Executive Square Suite 950, La Jolla, California 92093, US |
Technologies |
JavaScript,
HTML,
PHP
+24 more
(view full list)
|
Industry | Biotechnology Research |
Looking for a particular Longboard Pharmaceuticals employee's phone or email?
Brandi Roberts is the CFO of Longboard Pharmaceuticals.
44 people are employed at Longboard Pharmaceuticals.
Longboard Pharmaceuticals is based in La Jolla, California.